344 related articles for article (PubMed ID: 27788499)
1. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
[TBL] [Abstract][Full Text] [Related]
2. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
Neuner EA; Sekeres J; Hall GS; van Duin D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
[TBL] [Abstract][Full Text] [Related]
3. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
4. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
[TBL] [Abstract][Full Text] [Related]
5. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.
Wu TH; Huang FL; Fu LS; Chou CM; Chien YL; Huang CM; Lin CF; Chen PY
J Microbiol Immunol Infect; 2016 Oct; 49(5):717-722. PubMed ID: 25442872
[TBL] [Abstract][Full Text] [Related]
7. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
Patwardhan V; Singh S
Int Urol Nephrol; 2017 Sep; 49(9):1637-1643. PubMed ID: 28616818
[TBL] [Abstract][Full Text] [Related]
8. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.
Babiker A; Clarke L; Doi Y; Shields RK
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114856. PubMed ID: 31307867
[TBL] [Abstract][Full Text] [Related]
9. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
10. Fosfomycin: Mechanism and Resistance.
Silver LL
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28062557
[TBL] [Abstract][Full Text] [Related]
11. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
Matthews PC; Barrett LK; Warren S; Stoesser N; Snelling M; Scarborough M; Jones N
BMC Infect Dis; 2016 Oct; 16(1):556. PubMed ID: 27729016
[TBL] [Abstract][Full Text] [Related]
12. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
[TBL] [Abstract][Full Text] [Related]
13. Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant
Polat M; Ozkaya-Parlakay A; Tapısız A; Kara SS; Yüksel S
J Chemother; 2022 Apr; 34(2):97-102. PubMed ID: 34286658
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
16. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
[TBL] [Abstract][Full Text] [Related]
17. Fosfomycin-trometamol for Urinary Tract Infections in Kidney Transplant Recipients.
Ten Doesschate T; van Werkhoven H; Meijvis S; Stalenhoef J; van Zuilen A; de Vries A; Bonten M
Transplantation; 2019 Jun; 103(6):1272-1276. PubMed ID: 30130327
[TBL] [Abstract][Full Text] [Related]
18. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). II. Background of patients].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):494-508. PubMed ID: 8752863
[TBL] [Abstract][Full Text] [Related]
19. Fosfomycin for UTIs.
Drug Ther Bull; 2016 Oct; 54(10):114-117. PubMed ID: 27737907
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
